Mycofoli 180 Tablet contains Mycophenolate Sodium 180 mg, a selective immunosuppressant widely prescribed in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), leading to suppression of T- and B-lymphocyte proliferation, thereby reducing immune-mediated damage to transplanted organs. It is particularly suitable for patients requiring lower-dose or stepwise immunosuppression under specialist supervision.
Clinically, Mycofoli 180 Tablet is used in renal, hepatic, and cardiac transplant protocols, often as part of combination immunosuppressive therapy to maintain graft function and reduce rejection risk.
The tablet provides accurate dosing, consistent bioavailability, and dependable therapeutic outcomes, making it ideal for hospitals, transplant centers, specialty clinics, and pharmacies managing long-term post-transplant immunosuppressive care.